Quantitative immunohistochemistry for Evaluating the distribution of Ki67 and other Biomarkers in tumor sections and use of the method to study repopulation in xenografts after treatment with paclitaxel

Neoplasia

Volumn 14, Issue 4, 2012, Pages 324-334

  Fung, Andrea S ^a   Jonkman, James ^b   Tannock, Ian F ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD31 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; KI 67 ANTIGEN; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; FLUORESCENCE MICROSCOPY; HYPOXIA; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR RECURRENCE; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 84860612152     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.12346     Document Type: Article

References (32)

1. Wu L and Tannock IF (2003). Repopulation in murine breast tumors during and after sequential treatments with cyclophosphamide and 5-fluorouracil. Cancer Res 63, 2134-2138.
2. Huxham LA, Kyle AH, Baker JH, Nykilchuk LK, and Minchinton AI (2004). Microregional effects of gemcitabine in HCT-116 xenografts. Cancer Res 64, 6537-6541.
3. Kim JJ and Tannock IF (2005). Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 5, 516-525.
4. Primeau AJ, Rendon A, Hedley D, Lilge L, and Tannock IF (2005). The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 11, 8782-8788.
5. Tredan O, Galmarini CM, Patel K, and Tannock IF (2007). Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99, 1441-1454.
6. Jang SH, Wientjes MG, Lu D, and Au JL (2003). Drug delivery and transport to solid tumors. Pharm Res 20, 1337-1350.
7. Folkman J (2006). Angiogenesis. Annu Rev Med 57, 1-18.
8. Fukumura D and Jain RK (2007). Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 101, 937-949.
9. Hockel M and Vaupel P (2001). Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93, 266-276.
10. Vaupel P and Mayer A (2007). Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26, 225-239.
11. Rusnak DW, Alligood KJ, Mullin RJ, Spehar GM, Arenas-Elliott C, Martin AM, Degenhardt Y, Rudolph SK, Haws TF Jr, Hudson-Curtis BL, et al. (2007). Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. Cell Prolif 40, 580-594.
12. Vaupel P, Kallinowski F, and Okunieff P (1989). Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49, 6449-6465.
13. Olive PL, Vikse C, and Trotter MJ (1992). Measurement of oxygen diffusion distance in tumor cubes using a fluorescent hypoxia probe. Int J Radiat Oncol Biol Phys 22, 397-402.
14. Dewhirst MW (1998). Concepts of oxygen transport at the microcirculatory level. Semin Radiat Oncol 8, 143-150.
15. Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, Daenen LG, Man S, Xu P, Emmenegger U, et al. (2008). Rapid chemotherapyinduced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14, 263-273.
16. Scholz D and Schaper J (1997). Platelet/endothelial cell adhesion molecule-1 (PECAM-1) is localized over the entire plasma membrane of endothelial cells. Cell Tissue Res 290, 623-631.
17. Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, and Jain RK (1999). Taxaneinduced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res 59, 3776-3782.
18. Milas L, Hunter NR, Mason KA, Milross CG, Saito Y, and Peters LJ (1995). Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res 55, 3564-3568.
19. Kuh HJ, Jang SH, Wientjes MG, Weaver JR, and Au JL (1999). Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther 290, 871-880.
20. Tannock IF and Lee C (2001). Evidence against apoptosis as a major mechanism for reproductive cell death following treatment of cell lines with anti-cancer drugs. Br J Cancer 84(1), 100-105.
21. Brown JM and Attardi LD (2005). The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 5, 231-237.
22. Huang Q, Li F, Liu X, Li W, Shi W, Liu FF, O'Sullivan B, He Z, Peng Y, Tan AC, et al. (2011). Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med 17(7), 860-867.
23. Hirata A, Uehara H, Izumi K, Naito S, Kuwano M, and Ono M (2004). Direct inhibition of EGF receptor activation in vascular endothelial cells by gefitinib ("Iressa," ZD1839). Cancer Sci 95, 614-618.
24. Amin DN, Hida K, Bielenberg DR, and Klagsbrun M (2006). Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Res 66, 2173-2180.
25. Amin DN, Bielenberg DR, Lifshits E, Heymach JV, and Klagsbrun M (2008). Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells. Microvasc Res 76, 15-22.
26. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, et al. (2003). Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290, 2149-2158.
27. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabarbara P, and Bonomi P (2004). Determinants of tumour response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22, 3238-3247.
28. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, et al. (2005). Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353, 123-132.
29. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, et al. (2004). Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22, 777-784.
30. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, et al. (2004). Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22, 785-794.
31. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, et al. (2005). TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23, 5892-5899.
32. Fung AS and Tannock IF (2007). Potential of gefitinib to inhibit repopulation of tumor cells between courses of paclitaxel: implications for scheduling [abstract]. In Proceedings of the 98th Annual Meeting of the American Association for Cancer Research; 2007 Apr 14-18; Los Angeles, CA. American Association for Cancer Research, Philadelphia, PA. Abstract 5422.